Trials / Completed
CompletedNCT02061865
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN2176-3 |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-02-13
- Last updated
- 2015-02-11
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02061865. Inclusion in this directory is not an endorsement.